ESMO 25: Higher Dosage For Kelun/Merck’s Sac-TMT Behind OS Win In China NSCLC Study

 
• By Dexter Jie Yan
  
By administering a higher dose, Kelun-Biotech stayed ahead of Merck to yield the OS win for sac-TMT in non-squamous EGFR-mutated NSCLC in a second-line setting. (Shutterstock)

More from ESMO

More from Scrip